ClinicalTrials.gg
TerminatedNCT04725214Updated Nov 18, 2026

Anlotinib Combined With STUPP for MGMT Nonmethylated Glioblastoma

A Phase 2 interventional study of Anlotinib in MGMT-Unmethylated Glioblastoma, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Terminated at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
The trial was terminated early because free anlotinib was no longer available for newly enrolled patients.
Updated Nov 18, 2026Now TerminatedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 143 studies in Glioblastoma with a site in China — 74 open to participants now, 81 under way, 7 of them phase 3. Glioblastoma · China.

Enrollment
105th of 128
16 · median 36
Started
2021
with 13 others
Phase 2
35 of 143
17 open now
Registered
48th of 143
by date

Among the 143 studies in Glioblastoma with a site in China, this one is the 105th largest by enrollment of the 128 interventional ones that give a count, is one of 14 that started in 2021, is one of 35 in phase 2, and was the 48th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

74 of the 143 studies in Glioblastoma with a site in China are open now. Recruiting first, the newest first:

69 more — sign in →

All 74 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies in Glioblastoma with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to test the efficacy and safety of Anlotinib in combination with STUPP regimen for MGMT promoter nonmethylated glioblastoma.

Read the detailed description

For MGMT unmethylated glioblastoma patients undergoing STUPP regimen adjuvant therapy, during adjuvant chemotherapy, concurrent with anti-angiogenesis targeted therapy(Anlotinib capsule,d1-14).

03

Conditions studied

  • MGMT-Unmethylated Glioblastoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18-70 years,
  2. proven diagnosis of glioblastoma (WHO grade IV),
  3. Have received standard STUPP treatment plan,
  4. Gross resection or partial resection of the tumor (confirmed by MRI)> 50%,
  5. The pathological tissue specimens are detected as MGMT unmethylated,6. performance status ≥ 60,
  6. No previous radiotherapy, chemotherapy, immunotherapy or biotherapy 7.Adequate bone marrow function: ≥ 100g/L, ≥ 80×109/L, (ANC) ≥ 1.5×109/L

8.Adequate renal function: Serum creatinine ≤ 1.25 x UNL (upper normal limit) or ≥ 60 ml/min 9.Adequate hepatic function: serum ≤ 1.5 x UNL, and ALT ≤ 2.5 x UNL,ALP≤5x UNL 10.For females of , negative serum pregnancy test within 14 days prior to registration. Women of childbearing potential and male participants must practice adequate during participation in the study and within 8 weeks after the last administration of the drug 11.Able to provide written

Exclusion criteria

Exclusion Criteria:

  1. Recurrent or multiple malignant gliomas
  2. Subtentorial glioblastoma or lesions outside the skull
  3. Have received radiotherapy, chemotherapy or other anti-tumor drugs for the disease before surgery
  4. Previously received radiation therapy for the head and neck cancer
  5. Have received any antibody treatment before
  6. of radiotherapy and chemotherapy defined as follows: Acute bacterial or fungal infection,Unstable angina and/or congestive heart failure within the last 6 months,co-morbidity with therapy
  7. Evidence of bleeding diathesis or coagulopathy
  8. Prior invasive (except for non-melanomatous skin cancer or carcinoma in situ of cervix)
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Experimental

    For MGMT unmethylated glioblastoma, during temozolomide adjuvant, concurrent with anti-angiogenesis targeted therapy(Anlotinib capsule,d1-14)

    Drug: Anlotinib

Interventions

  • Anlotinib With STUPP Regimen

    Also known as: temozolomide capsule

06

What researchers measure

Primary outcomes

  1. 1-year OS

    1-year overall survival

    Time frame: from enrollment to death (for any reason).assessed up to 12 months

Secondary outcomes

  1. PFS

    Progression-Free Survival

    Time frame: from enrollment to progression or death (for any reason),assessed up to 24months

  2. OS

    Overall Survival

    Time frame: from enrollment to death (for any reason).assessed up to 24 months

  3. adverse event

    Adverse events are described in terms of CTC AE 5.0

    Time frame: from enrollment to death (for any reason).assessed up to 24 months

  4. Health-related quality of life

    Health-related quality of life are measured by the EORTC-QL30/BN20

    Time frame: from enrollment to death (for any reason).assessed up to 24 months

  5. Neurocognitive function

    Neurocognitive function are measured by John-Hopkins adapted cognitive exam (ACE)

    Time frame: from enrollment to death (for any reason).assessed up to 24 months

07

Study locations

1 site
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310009, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2021 to primary completion in Aug 2025, 54 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Dec 2022 → Aug 2025 and completion Dec 2023 → Aug 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2021
First posted
Jan 26, 2021
StartActual
Jan 15, 2021
Primary completionActual
Aug 4, 2025was Dec 2022
CompletionActual
Aug 4, 2025was Dec 2023
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Terminated The trial was terminated early because free anlotinib was no longer available for newly enrolled patients.
changed Nov 18, 2026
Primary completion
Dec 2022→Aug 4, 2025 (actual)
Nov 18, 2026
Study completion
Dec 2023→Aug 4, 2025 (actual)
Nov 18, 2026
Enrollment
33 (estimated)→16 (actual)
Nov 18, 2026
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University→Second Affiliated Hospital, Zhejiang University, School of Medicine
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Status unknown→Terminated
    Why stopped The trial was terminated early because free anlotinib was no longer available for newly enrolled patients.
    Primary completion Dec 2022→Aug 4, 2025 (now actual)
    Study completion Dec 2023→Aug 4, 2025 (now actual)
    Enrollment 33 (estimated)→16 (actual)
    Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University→Second Affiliated Hospital, Zhejiang University, School of Medicine
    + 4 other changes: identifiers, verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04725214
Collaborators
First Affiliated Hospital of Fujian Medical University, The First Affiliated Hospital of Soochow University, RenJi Hospital
Responsible party
Sponsor
First posted
Jan 26, 2021
Start date
Jan 15, 2021
Primary completion
Aug 4, 2025
Completion
Aug 4, 2025
Last update
Nov 18, 2026

Study contacts

Qichun Wei, MD
study chair · Second Affiliated Hospital, Zhejiang University, School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anlotinib

Start the discussion